Evaxion A (EVAX) Long-Term Debt Repayments (2022)

Evaxion A (EVAX) posted Long-Term Debt Repayments of -$30000.0 for Q2 2022, little changed on a QoQ basis from -$30000.0 in Q1 2022.

Evaxion A (EVAX) Long-Term Debt Repayments (2022) Analysis & Trends

Evaxion A's Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at -$30000.0 for Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.64 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Evaxion A	25.44 Mn	25.44 Mn	-	-

Download Data